WallStreetZenWallStreetZen

NASDAQ: LYRA
Lyra Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for LYRA

Based on 3 analysts offering 12 month price targets for Lyra Therapeutics Inc.
Min Forecast
$0.50+61.29%
Avg Forecast
$4.50+1,351.61%
Max Forecast
$11.00+3,448.39%

Should I buy or sell LYRA stock?

Based on 3 analysts offering ratings for Lyra Therapeutics Inc.
Buy
Strong Buy
1 analysts 33.33%
Buy
0 analysts 0%
Hold
2 analysts 66.67%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their LYRA stock forecasts and price targets.

LYRA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-05-07
lockedlocked$00.00+00.00%2024-05-07
lockedlocked$00.00+00.00%2024-03-25

1 of 1

Forecast return on equity

Is LYRA forecast to generate an efficient return?
Company
-74.73%
Industry
72.68%
Market
80.78%
LYRA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is LYRA forecast to generate an efficient return on assets?
Company
-40.92%
Industry
31.03%
LYRA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

LYRA earnings per share forecast

What is LYRA's earnings per share in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
-$1.18
Avg 2 year Forecast
-$0.81
Avg 3 year Forecast
-$1.22

LYRA revenue forecast

What is LYRA's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$1.4M-16.67%
Avg 2 year Forecast
$1.3M-24.7%
Avg 3 year Forecast
$11.3M+572.62%
LYRA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

LYRA revenue growth forecast

How is LYRA forecast to perform vs Biotechnology companies and vs the US market?
Company
69.97%
Industry
65.53%
Market
11.49%
LYRA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
LYRA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

LYRA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
LYRA$0.31$4.50+1,351.61%Buy
INDP$2.20$12.00+445.70%Buy
MEIP$2.81$7.00+149.11%Hold
IBIO$2.15$5.00+132.56%Strong Buy
CDT$0.25N/AN/A

Lyra Therapeutics Stock Forecast FAQ

Is Lyra Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: LYRA) stock is to Buy LYRA stock.

Out of 3 analysts, 1 (33.33%) are recommending LYRA as a Strong Buy, 0 (0%) are recommending LYRA as a Buy, 2 (66.67%) are recommending LYRA as a Hold, 0 (0%) are recommending LYRA as a Sell, and 0 (0%) are recommending LYRA as a Strong Sell.

If you're new to stock investing, here's how to buy Lyra Therapeutics stock.

What is LYRA's earnings growth forecast for 2024-2026?

(NASDAQ: LYRA) Lyra Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.35%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.86%.

Lyra Therapeutics's earnings in 2024 is -$68,877,000.On average, 5 Wall Street analysts forecast LYRA's earnings for 2024 to be -$72,060,463, with the lowest LYRA earnings forecast at -$81,083,262, and the highest LYRA earnings forecast at -$55,478,022. On average, 4 Wall Street analysts forecast LYRA's earnings for 2025 to be -$49,533,948, with the lowest LYRA earnings forecast at -$74,986,777, and the highest LYRA earnings forecast at -$17,070,161.

In 2026, LYRA is forecast to generate -$74,377,128 in earnings, with the lowest earnings forecast at -$74,377,128 and the highest earnings forecast at -$74,377,128.

What is LYRA's revenue growth forecast for 2024-2026?

(NASDAQ: LYRA) Lyra Therapeutics's forecast annual revenue growth rate of 69.97% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.53%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.49%.

Lyra Therapeutics's revenue in 2024 is $1,680,000.On average, 3 Wall Street analysts forecast LYRA's revenue for 2024 to be $85,350,803, with the lowest LYRA revenue forecast at $30,482,430, and the highest LYRA revenue forecast at $129,855,150. On average, 2 Wall Street analysts forecast LYRA's revenue for 2025 to be $77,120,547, with the lowest LYRA revenue forecast at $57,306,967, and the highest LYRA revenue forecast at $96,934,126.

In 2026, LYRA is forecast to generate $688,902,907 in revenue, with the lowest revenue forecast at $688,902,907 and the highest revenue forecast at $688,902,907.

What is LYRA's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: LYRA) forecast ROA is -40.92%, which is lower than the forecast US Biotechnology industry average of 31.03%.

What is LYRA's Price Target?

According to 3 Wall Street analysts that have issued a 1 year LYRA price target, the average LYRA price target is $4.50, with the highest LYRA stock price forecast at $11.00 and the lowest LYRA stock price forecast at $0.50.

On average, Wall Street analysts predict that Lyra Therapeutics's share price could reach $4.50 by May 7, 2025. The average Lyra Therapeutics stock price prediction forecasts a potential upside of 1,351.61% from the current LYRA share price of $0.31.

What is LYRA's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: LYRA) Lyra Therapeutics's current Earnings Per Share (EPS) is -$1.20. On average, analysts forecast that LYRA's EPS will be -$1.18 for 2024, with the lowest EPS forecast at -$1.33, and the highest EPS forecast at -$0.91. On average, analysts forecast that LYRA's EPS will be -$0.81 for 2025, with the lowest EPS forecast at -$1.23, and the highest EPS forecast at -$0.28. In 2026, LYRA's EPS is forecast to hit -$1.22 (min: -$1.22, max: -$1.22).

What is LYRA's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: LYRA) forecast ROE is -74.73%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.